WuXi Biologics Achieves Highest ESG Rating Tier from Morningstar Sustainalytics

WuXi Biologics has been granted a negligible-risk ESG rating by Morningstar Sustainalytics, ranking in the top 1% globally. The company has also been recognized as an Industry and Regional ESG Top-Rated Company for five consecutive years. WuXi Biologics is a leader in Green CRDMO and is committed to enhancing sustainability capabilities and promoting responsible practices throughout the value chain.

WuXi Biologics (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), has been awarded a negligible-risk ESG rating by Morningstar Sustainalytics, placing it in the top 1% globally. This achievement underscores the company's commitment to sustainability and responsible business practices.

The ESG rating, announced on July 16, 2025, reflects WuXi Biologics' strong performance in managing environmental, social, and governance (ESG) risks. The company has consistently demonstrated excellence in ESG metrics, having been recognized as an Industry and Regional ESG Top-Rated Company for five consecutive years. This accolade is a testament to WuXi Biologics' dedication to sustainability and its leadership in the Green CRDMO sector.

WuXi Biologics' CEO and Chairman of the ESG Committee, Dr. Chris Chen, commented on the achievement, stating, "We are very pleased to have achieved the negligible-risk rating from Morningstar Sustainalytics. It is a reflection of and recognition for WuXi Biologics' continuous commitment to enhancing sustainability capabilities. As a global leader in Green CRDMO, we are focused not only on delivering our own ESG excellence but also on enabling partners worldwide to fulfill their ESG commitments, collaborating with all stakeholders to promote responsible practices throughout the entire value chain."

The ESG rating from Morningstar Sustainalytics is based on a comprehensive assessment framework that evaluates over 20 material ESG issues through more than 200 indicators. WuXi Biologics' high score is a result of its robust risk management and low risk exposure, placing it in the top tier of global companies.

WuXi Biologics' commitment to sustainability is evident in its numerous accolades and recognitions. The company has been granted a MSCI AAA rating, awarded an EcoVadis Platinum Medal, and listed in the Dow Jones Sustainability Indices (DJSI). It has also been named to the CDP Water Security "A list" and given an A- CDP Climate Change leadership-level score since 2023. Additionally, WuXi Biologics is a constituent of the FTSE4Good Index Series, listed in the Hang Seng ESG 50 Index, and rated as Prime by ISS ESG Corporate Rating.

By achieving a negligible-risk ESG rating, WuXi Biologics not only demonstrates its own commitment to sustainability but also sets an example for the industry. The company's focus on green technology innovations and responsible practices aligns with the global trend towards sustainable business models. As investors and financial professionals continue to prioritize ESG factors, WuXi Biologics' strong ESG performance positions it as a leader in the CRDMO sector.

References:
[1] https://www.prnewswire.com/news-releases/wuxi-biologics-granted-highest-negligible-risk-esg-rating-from-morningstar-sustainalytics-302506622.html
[2] https://www.marketscreener.com/quote/stock/WUXI-BIOLOGICS-CAYMAN-INC-120796697/news/WuXi-Biologics-Granted-Highest-Negligible-Risk-ESG-Rating-from-Morningstar-Sustainalytics-50522726/